Caas Capital Management LP Aprea Therapeutics, Inc. Transaction History

Caas Capital Management LP

$836 Million
Q3 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 17, 2021	SELL	$4.73 - $8.15 $870,665 - $1.5 Million	-184,073 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$4.92 - $30.67 $905,639 - $5.65 Million	184,073 New	184,073 $906,000
Q3 2020 Nov 09, 2020	SELL	$21.66 - $38.86 $131,237 - $235,452	-6,059 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$25.47 - $39.69 $154,322 - $240,481	6,059 New	6,059 $235,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,688
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.